Complement Activation, Immunogenicity, and Immune Suppression as Potential Side Eff ects of Liposomes - Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications - page 329

37. Gabizon, A., Tzemach, D., Mak, L., Bronstein, M., and Horowitz, A. T.
(2002). Dose dependency of pharmacokinetics and therapeutic efficacy
of pegylated liposomal Doxorubicin (DOXIL) in murine models. J. Drug
Targeting 10, pp. 539-548.
38. Gill, P. S., Espina, B. M., Muggia, F., Cabriales, S., Tulpule, A., Esplin, J. A.,
Liebman, H. A., Forssen, E., Ross, M. E., and Levine, A. M. (1995). Phase
I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.
J. Clin. Oncol . 13, pp. 996-1003.
39. Gill, P. S., Wernz, J., Scadden, D. T., Cohen, P., Mukwaya, G. M., von
Roenn, J. H., Jacobs, M., Kempin, S., Silverberg, I., Gonzales, G., Rarick,
M. U., Myers, A. M., Shepherd, F., Sawka, C., Pike, M. C., and Ross, M. E.
(1996). Randomized phase III trial of liposomal daunorubicin versus
doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's
sarcoma. J. Clin. Oncol . 14, pp. 2353-2364.
40. Girard, P. M., Bouchaud, O., Goetschel, A., Mukwaya, G., Eestermans,
G., Ross, M., Rozenbaum, W., and Saimot, A. G. (1996). Phase II study
of liposomal encapsulated daunorubicin in the treatment of AIDS-
associated mucocutaneous Kaposi's sarcoma. AIDS 10, pp. 753-757.
41. Guaglianone, P., Chan, K., DelaFlor-Weiss, E., Hanisch, R., Jeff ers, S.,
Sharma, D., and Muggia, F. (1994). Phase I and pharmacologic study
of liposomal daunorubicin (DaunoXome). Invest. New Drugs 12, pp.
103-110.
42. Hamad, I., Al-Hanbali, O., Hunter, A. C., Rutt , K. J., Andresen, T. L.,
and Moghimi, S. M. (2010). Distinct polymer architecture mediates
switching of complement activation pathways at the nanosphere-
serum interface: implications for stealth nanoparticle engineering.
ACS Nano 4, pp. 6629-6638.
43. Harashima, H., Sakata, K., Funato, K., and Kiwada, H. (1994). Enhanced
hepatic uptake of liposomes through complement activation depending
on the size of liposomes. Pharm. Res. 11, pp. 402-406.
44. Harris, C. L., and Morgan, B. P. (2004). The many faces of the membrane
regulators of complement, In The Complement System: Novel Roles in
Health and Disease (J. Szebeni, ed.). Kluwer, Boston.
45. Hashimoto, Y., Sugawara, M., and Endoh, H. (1983). Coating of
liposomes with subunits of monoclonal IgM antibody and targeting of
the liposomes. J. Immunol. Methods 62, pp. 155-162.
46. Hastings, K., L,. (2002). Implications of the new FDA/CDER
immunotoxicology guidance for drugs. Int. Immunopharmacol . 11, pp.
1613-1618.
47. Haxby, J. A., Gotze, O., Muller-Eberhard, H. J., and Kinsky, S. C. (1969).
Release of trapped marker from liposomes by the action of purified
complement components. Proc. Natl. Acad. Sci. U.S.A. 64, pp. 290-295.